Allogene raises another $120m to develop ‘off-the-shelf’ CAR-Ts
September 07, 2018 / Richard Staines
Investors have backed US biotech Allogene and its off-the-shelf CAR-T technology to the tune of $120 million in a second funding round.
Participants were mainly first-time investors – led by Perceptive Advisors, other backers included Deerfield Management Company, Fidelity Management, and Research Company, Franklin Templeton Investments on behalf of certain clients, and Surveyor Capital.
Also on board were funded and accounts advised by T. Rowe Price Associates, Inc., the University of California Office of the Chief Investment Officer, venBio Select Advisor, as well as additional large mutual funds.